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Mutations in the codon for a conserved arginine.1563 in the COL4A5
collagen gene in Alport syndrome. We have screened 110 unrelated
Alport syndrome kindreds for mutations in the exon 48 region of the
COL4A5 collagen gene. Denaturing gradient gel electrophoresis(DGGE) of the PCR-amplified region of exon 48 revealed sequence
variants in DNA from affected males and carriers of three unrelated
kindreds. All three kindreds have classical Alport syndrome of the
juvenile type. DNA-sequencing analyses demonstrated two different
single base changes in the codon for arginine-1563 located in exon 48. In
Utah kindred 2103, there was a substitution of C by T resulting in the
change of the CGA codon for arginine to the translation stop codon
TGA. In Utah kindred 2123 and in the Danish kindred Al3, there was
a C —p T mutation in the noncoding strand changing the same codon to
CAA for glutamine. Both mutations were confirmed by allele-specific
hybridization on PCR-amplified DNA from other family members.
Alport syndrome (AS) is a dominantly inherited form of
progressive hereditary nephritis frequently associated with sen-
sorineural hearing loss and also ocular lesions such as lentico-
nus and macular flecks [1, 21. The disease is mainly inherited as
a dominant X chromosome-linked trait with an estimated inci-
dence of 1:5000. Autosomal dominant forms have also been
reported. Clinically, AS is a heterogeneous disease, and has
been classified into six types based on inheritance, onset of
end-stage renal disease (ESRD) and presence of hearing loss
[2]. According to this classification, type I is classic juvenile AS
with sensorineural hearing loss, wherein autosomal versus
X-linked inheritance cannot be determined by segregation anal-
ysis because affected males have no offspring. Type II is
X-linked juvenile nephritis and hearing loss. Type III is
X-linked adult nephritis and hearing loss. Type IV is X-linked
adult nephritis with no known extrarenal abnormalities. Type V
(Epstein syndrome) is autosomal nephritis, hearing loss, and
thrombocytopathy. Type VI is autosomal juvenile nephritis and
hearing loss. In general, electron microscopy usually reveals
thinning and thickening of the glomerular basement membrane
(GBM) with splitting of the lamina densa. These changes are
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presumably due to structural defects in the basement membrane
network since mutations have been found in the gene
(COL4A5) for the GBM-specific type IV collagen aS chain in
X-linked AS [3—12].
Type IV collagen forms the structural skeleton of the GBM as
well as other basement membranes [13]. Each molecule has a
triple-helical structure composed of three a chains which can be
of types al(IV), cs2(IV), a3(IV), a4(IV) or a5(IV) [13—18]. The
al(IV) and a2(IV) are found in most ii not all basement
membranes, whereas the a5(IV) chain has restricted distribu-
tion. In the kidney, the a5(IV) chain is found only in the GBM,
indicating that this chain has a special role for that structure
[171. The mammalian a chains, which have molecular weights
of about 170,000 to 185,000, contain long Gly-X-Y-repeat se-
quences which are interrupted 21 to 23 times by noncollagenous
sequences. At the carboxyl terminal end, each a chain has a
highly conserved 26 to 28 kDa noncollagenous domain (NC
domain). The NC domain, which has a highly conserved
primary structure, is believed to be essential for the folding of a
chains into a triple helix. It also contains evolutionarily con-
served cysteine residues which participate in the formation of
intermolecular cross links. Following secretion from the cell,
the type IV collagen molecules aggregate in a complex manner
end-to-end and by lateral alignment, forming the supramolecu-
lar basement membrane network structure stabilized by inter-
molecular disulfide bonds. The human COL4A5 gene which is
located on Xq22 has recently been shown to contain 51 exons
[18, 19]. Since the sequence and number of exons in the
COL4A5 gene have now been elucidated [19], the exons can
now be numbered from the 5' end of the gene. Thus, the
previously described exons Ito 19 from the 3' end [18] are now
referred to as exons 33 and 51, respectively, and all other exons
accordingly.
Several mutations have been described in the COL4A5 gene
in AS patients [3—12]. These mutations include different types of
major gene rearrangements such as deletions, inversions, inser-
tions and duplications as well as point mutations dispersed
throughout in the gene. A striking feature is that, thus far, the
same mutation has not been found in unrelated kindreds indi-
cating the absence of a "major AS mutation" or hot spots in the
gene. In the present paper we describe two single base muta-
tions in the codon for arginine-1563 in exon 48. A mutation in
722
E48A 48AE
cgcagtcctttactgttttctctccaaatctttcta4 CGqCTGGCAGCtflCj
1504[Se
(GC) 2448BE-GC I
.4
AcnAmAcmncTmcTGGcTcTcmcccCAGAGcccATGccMqacnuccc?aflflAspTyr$e
gtaaggcattgatttagctgtgact
1563
E48B
tttaccaatccccactta9tta9cta9tc
Zhou et a!: COL4A5 mutations in A/port syndrome 723
Fig. 1. Design of primers for PCR
amp1fication of the exon 48 region. The
nucleotide sequence of exon 48 (shaded
pattern) is shown by capital letters and the
adjacent intron sequences by lower case
letters. The predicted amino acid sequence is
also shown with residue numbering according
to Zhou et al (1992a). The primer pair E48A/
E48B (arrows) was made solely according to
intron sequences. The primer pair 48AE/
48BE-GC (arrows) was made with 48AE
covering a part of the 5' end of the exon and
the adjacent intron and 48BE-GC having a
48-nucleotide long GC tail as illustrated.
Utah kindred 2103 generates a translation stop codon. The
other mutation common to two other unrelated kindreds, Utah
2123 and Danish kindred A13, results in the substitution of
glutamine for arginine.
Methods
Pedigrees
Members of K2103, of European extraction, are scattered
across the United States. The male proband showed proteinuria
and microscopic hematuria at age two years. He developed
hypertension at age 12, developed ESRD at age 23 and received
a renal transplant, which continues to function well at his
present age of 29. Sensorineural hearing was detected at age 11,
but ophthalmological examination revealed no abnormalities.
At age 69 years, the mother of the proband reports bilateral
hearing loss, lifelong microscopic hematuria, but the father
does not have relevant symptoms. Two brothers at ages 42 and
43 years, and two sisters at ages 40 and 46 years report no renal,
audiologic, ophthalmologic, or hematologic abnormalities. The
COL4A5 markers 1201 tested were fully informative in this
family. There was no inconsistency with linkage to COL4A5
(Lod 1.16).
Members of K2l23 are of European extraction. The male
proband showed proteinuria and microscopic hematuria at age
five years and he had early bilateral sensorineural hearing loss.
At age 15, electron microscopy of a renal biopsy showed
thickness variations and "moth-eaten appearance" of glomer-
ular basement membranes. At age 21 he reports no ophthalmo-
logic or hematologic abnormalities. His sister reports protein-
uria and microscopic hematuria since age three. The mother,
now aged 44 years, had constant proteinuria and microscopic
hematuria since age five. She reports no abnormalities of
hearing, vision, or blood. At age 58 years, the father of the
proband and of his sister, their maternal grandfather at 73, their
maternal uncle at 40, and their maternal aunt at 43 all report no
relevant symptoms. No member of this kindred has had a
kidney transplant.
A Danish kindred Al3 comprises a large family with history
of renal disease for at least three generations. The proband is a
36-year-old male with a juvenile form of Alport syndrome.
Hematuria and proteinuria were detected at the age of eight,
and the disease progressed to terminal renal failure at the age of
29. Renal biopsy was not performed. He received a kidney
transplant at the age of 29 which is still well functioning. A
hearing defect was detected at the age of seven which has
progressed steadily since. His sister and his mother's sister
both have hematuria and proteinuria since childhood. No
hematuria or proteinuria have been detected in the proband's
mother, but sensorineural hearing loss was detected by audio-
metric testing at the age of 53. The mother's brother died at age
27 in chronic renal failure. He had a marked reduced hearing
and ophthalmoscopy revealed an irregular refraction in both
lenses, but slit-lamp examination was never performed. The
proband's maternal grandmother had hematuria, proteinuria
and reduced hearing. She died at 78 years of age. No foam cells
were present in the interstitium. Electron microscopy of one
total glomerular cross section showed normal basic structure
and no deposits were present. There was, however, a slight,
abnormal variation in peripheral basement membrane thickness
and the lamina densa was focally very thin. Slight splitting of
the lamina densa was present focally.
The other 107 kindreds which formed a part of this study
derive from Denmark, Finland, Germany, Sweden and USA.
The affected males of these kindreds have clinically been
diagnosed to have AS with hematuria and end-stage renal
failure with or without hearing loss and ocular lesions.
Design of primers for polymerase chain reaction
ampljfication of exon 48 region
Total genomic DNA isolated from leukocytes from different
individuals was regionally amplified by PCR [21, 22]. Briefly, 50
ng of DNA was used as template in each reaction. In the case of
the hemizygous proband, 25 ng of patient DNA and 25 ng of
normal male DNA was used as mixed template to artificially
generate heterozygous DNA, as it is easier to observe a point
mutation by DGGE from heterozygous than hemizygous DNA.
The primer pair E48A and E48B was made complementary to
sequences up- and downstream from the exon, as illustrated in
Figure 1. Based on the melting map analysis (Fig. 2A), the PCR
product made with these primers would reveal most sequence
724 Zhou et al: COL4A5 mutations in Alport syndrome
0a
100
go
80
70
60
E48A
Fig. 2. Melt map analyses of two PCR products made for exon 48 with the two primer pairs illustrated in Fig. 1. The x-axis indicates base pairs
of the PCR product starting from the 5' end. The locations of primers are indicated below by arrows. The computer program predicts the melting
temperature (y-axis) for different regions of the PCR product. The location of the exon and intron sequences of the amplified DNA are indicated
above and by vertical dashed lines. (A) PCR product made with primer pair E48A/E48B (see Fig, 1) has the highest temperature melting domain
in the region at the 5' end border of the exon. The position of the two single base mutations identified at the 3' end of the exon sequence in the
three kindreds studied here is marked by an arrow. (B) PCR product made with primer pair 48AE/48BE-GC has the highest temperature melting
domain in the region generated by the 48-nucleotide long GC sequence. Therefore, the DOGE should disclose the sequence variants in the 5' end
of the exon.
variants, except in about 30 bases at the 5' end of the exon and
in the adjacent intron region which serve as a natural GC clamp
containing the highest melting domain [23]. Therefore, another
set of primers, 48AE and 48BE-GC containing a 48 nucleotide
GC sequence, was made to generate a PCR product which
should reveal sequence variants in the rest of the exon sequence
(Fig. 1). The melt map analysis of this PCR product is shown in
Figure 2B. As can be seen, the highest melting domain now
resides in the region of the GC clamp located in the 3' half of the
exon. Therefore, DGGE analysis of the two different PCR
products made for exon region 48 should disclose sequence
variation both within the exon region as well as in the immedi-
ately adjacent intron sequences. The melt map analyses were
carried out using the computer program EZMELT (JSB Com-
puter Services, Newtonville, Massachusetts, USA).
The amplification reactions were carried out using Ampli Taq
DNA polymerase (Perkin Elmer Cetus) according to the proto-
cols of the manufacturer. The samples were first denatured by
heating to 94°C for five minutes, followed by 40 thermal cycles
consisting of heat denaturation at 94°C for 30 seconds, cooling
to 48°C for 30 seconds to anneal the primers and then extension
at 72°C for 30 seconds. After five minutes of the final extension
at 72°C, the whole reaction mixture was denatured at 94°C for
five minutes, and cooled to 45°C for 15 mm for the formation of
Denaturing Gradient Gel Electrophoresis (DGGE)
In order to search for small or point mutations in the
PCR-amplified exon regions, parallel DGGE was first carried
out [24, 25]. The gels were prepared with a vertical linear
gradient from 20% (top) to 80% denaturant (bottom). The 100%
denaturant stock solution contained 6.8% acrylamide, 40%
formamide and 7 M urea in TAE buffer (40 m Tris, 20 mM
sodium-acetate, 1 mts EDTA, pH 7.4). The 0% denaturing
solution contained 6.8% acrylamide in TAE buffer. For prepa-
ration of the gradient gel, 12 ml of each denaturant, mixed with
70 tl of 20% ammonium persulfate and 70 d TEMED, was
poured into the gradient maker (Sa 100 gradient maker, Hoefer
Scientific Instruments). The samples were electrophoresed at
60°C.
DNA sequencing
The genomic DNA from individuals with abnormal patterns
on the denaturing gradient gels was reamplified without mixing
it with normal DNA. A sample of I j.d (about 80 ng) of purified
PCR product was added as template to the cycle sequencing
reaction mixture. The reaction mixture consisted of a d/ddNTP
mix, 0.4 pmolI4u1 fluoresceine-labeled primer (Fluore PrimeTM,
Pharmacia), 4 units Ampli Taq DNA polymerase (Perkin-
A
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Fig. 3. DGGE of PCR-ampl{/ied exon 48
region of the COL4A5 gene in Utah kindreds
K2103 and K2123 and the Danish kindred
II. A13. DNA from affected males was mixed
with normal DNA. The exon 48 region was
amplified by PCR using the primer pairs
" illustrated in Fig. 1 and applied to a DGGE
analysis gel, essentially as described in
Methods. Abnormal migration was observed in
samples from the female carriers and the
proband of the two Utah kindreds K2l03 and
K2123 and the Danish kindred A13. The PCR
products were run in a 20 to 80% denaturant
gradient at 200 V for two hours.
mM Tris-HCI, pH 8.9 at room temperature, 20 mM ammonium
sulfate, and 5 mrvi MgCl2. The reaction was carried out in
microtubes (2000 Micro Amp Reaction tubes) in a Perkin-Elmer
Cetus GeneAmp PCR system 9600. The total reaction volume
was 5 pA. The conditions were 15 cycles of 95°C for 15 seconds,
55°C for 15 seconds, and 70°C for 45 seconds. This was followed
by another 15 cycles of 95°C for 15 seconds, and 70°C for 45
seconds. The reaction mixtures were denatured with 4 M1 of
formamide at 95°C for three minutes and sequenced on an
Automated Laser Fluoroscent DNA Sequencer (Pharmacia,
LKB).
Allele-spec jfic hybridization
Allele-specific hybridization was carried out to analyze the
presence or absence of the mutation among the family mem-
bers. PCR amplification of exon 48 was performed. Duplicate
filters were made by loading 7 pA of the PCR amplified product
to the two parallel slots of a slot-blot apparatus (Schleicher
Schuell, S&S Minifold II) containing a nitrocellulose filter.
Each filter was hybridized either with the y-32P-labeled 15-mer
normal 3E48N (5'-CAT TAG TCG GTA AGG-3') or mutant
3E48P136 (5'-CAT TAG TTG GTA AGG-2') and 3E48P165
(5'-CAT TAG TCA GTA AGG) oligonucleotide probe at 37°C
overnight. Washing was performed once by lx SSC, 0.1% SDS
at room temperature and then by soaking in the same solution at
37°C for one hour for the mutant oligonucleotide or two hours at
37°C for the normal oligonucleotide.
Results
Southern analysis of kindreds
Southern hybridization analysis was carried out on total
genomic DNA from affected males of Utah kindreds K2l03 and
K2l23 and of the Danish kindred Al3 using cDNA probes
(JZ-4, HT-14. PL-31, MD-6 and PL-4) spanning the entire
COL4A5 collagen gene [6, 171. Analysis of DNA digested with
several restriction enzymes did not reveal any major gene
rearrangements or restriction fragment length polymorphisms
(data not shown).
PCR ampljflcation and DGGE analysis of the exon 48 region
Since the Southern analysis did not reveal the presence of
mutations in the DNA from the three kindreds, the DNA was
subjected to systematic search for point or small mutations in
individual exon and their adjacent intron regions. The approach
applied was to amplify separately the exon region by PCR,
followed by analysis of the PCR fragments by DGGE. In the
case of the three kindreds studied here, PCR amplification and
subsequent parallel DGGE analyses of the exon 48 region
revealed abnormal migration pattern in the probands and the
carrier females (Fig. 3). These findings indicated sequence
variation within or immediately adjacent to exon 48.
Identification of single base mutations
Having found evidence for sequence variation in exon 48, the
PCR-amplified exon 48 were sequenced. Since male patients are
hemizygous for the X chromosome, the DNA of male patients
was analyzed. Two different single base changes were demon-
strated, in different individuals, in the arginine-l563 codon of
exon 48. In Utah kindred 2103, there was a C —+ T substitution
in the coding strand. The finding was confirmed by repeated
sequencing of both strands. This mutation changed the codon
CGA for arginine to the translation stop codon TGA (Fig. 4).
The presence of this point mutation was confirmed by allele-
specific hybridization, showing that the proband was hemizy-
gous for the mutation and his mother heterozygous (Fig. 5).
Controls only gave signals with probes containing the normal
sequence.
Sequencing analyses of the DNA samples from the male
patients from Utah kindred 2123 and the Danish kindred Al3
demonstrated the presence of the same single base change C —*
T in the non-coding strand of exon 48. This mutation changes
the CGA codon of arginine-1563 to CAA for glutamine (Fig. 4).
As for the mutation above, allele-specific hybridization demon-
strated that the probands are hemizygous for the mutation, their
mother and female relative carriers being heterozygotes (Fig.
5). Analyses of 20 control samples gave positive signals with the
control probe only (data not shown).
Discussion
The present work resulted in the identification of single base
mutations in the two first bases of the codon for arginine at the
3' end of exon 48 (counted from the 5' end) in the COL4AS gene
in juvenile type classical Alport syndrome. These mutations,
COL4A5
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Fig. 4. (A) Location of single base mutations
in exon 48 of the COL4A5 gene in Utah
kindreds K2103 and K2123 and the Danish
kindred A13. At the top, a scheme of the 3'
end of the gene with exons shown as shaded
boxes and numbered from the 5' end
according to Zhou et al (1992c). Below; The
two single base mutations in exon 48 change
the codon CGA (boxed) for arginine-1563,
located in exons 48 and 49, to the translation
stop codon TGA (kindred K2103) and to the
CAA codon for glutamine (kindreds K2123
and A 13). Capital letters, exon sequences;
lower case letters, intron sequences. The
numbers of the amino acid residues are shown
below the amino acids. (B) Schemes of the
a5(IV) collagen chain illustrating the effects of
the mutations. The mutation in kindred K2l03
would, if the mRNA were translated
normally, results in an abnormally short chain
containing 1562 amino acids instead of 1685.
The mutation in kindreds K2l23 and A13
would substitute an arginine in the center of
the NC domain with glutamine. The black box
represents the signal peptide; white pattern,
the collagenous Gly-X-Y-repeat sequences
and; shaded boxes, interruptions in the
collagenous sequences and NC domain which
has two symmetrical halves (I and II).
which have not been reported before, can be considered causal
for the disease in the patients involved.
The mutation of Utah kindred 2103 converting the arginine
codon CGA to a translation stop codon TGA would, if trans-
lated correctly, result in a shortened translated sequence lead-
ing to the formation of an a5(IV) chain containing only 1562
residues instead of 1685 (Fig. 4B). This would mean an NC
domain with only about one-half of its normal size of 227
residues. Such a chain cannot be functionally normal in the
GBM structure. This postulation is supported by other data [3,
4, 8, 10, 12] where AS patients have partial COL4A5 gene
deletions leading to absence or abnormal primary structure of
a5(IV) chains.
The effect of the other mutation, changing the arginine- 1563
codon CGA to CAA for glutamine is less obvious. Arginine is a
highly hydrophilic, positively charged amino acid containing a
long side chain with a guanidinium group, whereas glutamine is
an uncharged amino acid with a smaller side chain. The
expected effect of the amino acid substitution would be a mild
decrease in polarity of this region. Despite these apparently
mild effects, the amino acid substitution is postulated to be
causal for the disease for two major reasons. First of all, the
mutated arginine-1563, located in the globular carboxyl terminal
NC domain of the a5(IV) chain, is a conserved amino acid. It
has been conserved during evolution in both symmetrical
halves of the NC domain of all known type IV collagen a chains
from Drosophila to human. The NC domain is thought to be
important for correct alignment of three a chains prior to triple
helix formation, and it contains cysteine residues that form
disulfide bonds between molecules [5, 26]. Therefore, the
correct structure and conformation of the NC domain is essen-
tial for supramolecular assembly. The importance of the NC
domain is emphasized by its conserved primary structure which
is extraordinarily well conserved in all known type IV collagen
a chains from Drosophila [27], C. elegans [28], mouse [29],
bovine [30, 31] and human [7, 17, 32—35]. The NC domain of
type IV collagen a chains which has 227 to 233 residues, has
two homologous halves, each containing six cysteine residues
at identical positions. The substituted arginine studied in the
present work is located next to cysteine-1564 which participates
in intermolecular cross links with the NC domain of another
chain [26]. Both amino acids are conserved in both symmetrical
halves of the NC domain in all known type IV collagen a chains
(Fig. 6). The actual role of arginine at this location in the a
chains of type IV collagen is not known, but arginine residues
have been shown to have an important stabilizing role in many
proteins by contributing to hydrogen bonds by the guanidinium
group [36]. It can be surmised that the mutation interferes with
the formation or stability of this disulfide bond and adjacent
hydrogen bonds and, thereby, weakens the GBM structure.
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Two lines of evidence indicate that the mutation is causal for
the disease. First of all, we have shown previously that a
mutation substituting the adjacent residue cysteine-1564 to
serine [5] causes adult type Alport syndrome (AS). However, it
is not clear why the presently reported arginine-1563 to glu-
tamine mutation gives rise to a juvenile onset AS, while the
cysteine-1564 to serine mutation leads to a milder adult type
AS. It is possible that: (1) there is another disease causing
mutation in the kindreds and that the arginine-l563 codon is
polymorphic or (2) that the G —÷ A base change present in the
(—1) position of the donor splice site results in less efficient
splicing or exon skipping. Both types of splicing defects could
result in a severe disease phenotype. A second argument for the
arginine-1563 mutation being causal for AS is that it segregated
with the phenotype in both affected kindreds.
To date, a number of different mutations have been reported
in the COL4A5 gene in Caucasians from USA and Europe
[3—12]. These mutations include both deletions and other major
gene rearrangements as well as single base point mutations. The
single base mutations published thus far are in exons 17, 23, 38,
48 and 49. All the mutations differ between kindreds. This has
indicated that a "major mutation(s)" does not exist for AS,
which in turn can hinder extensive population screening where
Fig. 5. Allele-specific hybridization analysis
-> TGA ofPCR-amplfied exon 48 region from Utah
Stop kindreds K2103 and K2123 and the Danish
kindred A13. DNA from affected males are
positive for the mutant oligonucleotide
probes, and female carriers are positive for
both the mutant allele and the normal probe.
Non-carriers are positive only for the normal
probe.
Fig. 6. Evolutionary conservation of residues
corresponding to arginine-1563 in the human
a5(IV) chain and its adjacent residues. The
arginine (shaded box) is conserved in both
symmetrical halves of the NC domain in all
known type IV collagen a chains. Also, most
of the immediate neighboring amino acids
(boxed), including two cysteines are
conserved. For references, see text.
required. However, since only a fraction of defects have been
identified in COL4A5 in AS, the presence of a major mutation
in that or another X chromosome gene cannot be excluded. The
present findings are of particular interest, firstly because two
different point mutations were found in the same codon and,
secondly because the findings also represent the first example of
the same single base mutation in the COL4A5 gene in unrelated
kindreds. Thirdly, these arginine- 1563 mutations generate juve-
nile type classical AS while mutation of the neighboring residue
cysteine-1564 results in adult onset AS. The mutation, present
in exon 48, changing the codon of arginine to glutamine, was
found in two out of 110 kindreds that we have studied by DGGE
analysis of the PCR-amplified exon region. Interestingly,
Smeets et al [12] have also found this same mutation in one out
of 20 Dutch Alport patients studied. On the basis of this fact, it
may not be justified to call it a "major mutation" in analogy to
the major mutation zF5O8 found in almost 70% of the patients
with cystic fibrosis [37]. However, this codon may represent a
hot spot in the COL4A5 gene highly susceptible to mutagenic
effects. Therefore, this particular region should be analyzed in
as many patients as possible.
The two mutations described here are good examples of the
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most common types of single base mutations in human dis-
eases. Both mutations involved a CpG dinucleotide resulting in
C — T substitutions. One mutation converted a CG to TG on
the coding strand changing the CGA codon for arginine to the
translation stop codon TGA, and the other converted a CG to
TG on the non-coding strand resulting in the conversion of the
same CGA codon for arginine to CAA for glutamine. The
mechanism of this type of mutations is thought to relate with the
propensity of cytosines at CpG dinucleotides to methylate and
to spontaneously deaminate to thymines.
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